All-optical high-throughput systems allow simultaneous high resolution action potential (AP) 
Introduction
Optical approaches offer contact-free high-resolution measurements of key electromechanical parameters in cardiomyocytes, e.g. action potentials (AP), Ca 2+ transients (CaTr), or contraction. Recently, all-optical highthroughput systems allowed simultaneous AP and CaTr measurements from cardiomyocytes within multicellular context, offering means to speed up in vitro drug tests [1, 2] . In this work, we aim (i) to calibrate/optimize populations of in silico models of human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) by means of simultaneous optically recorded data of APs and CaTrs in control conditions and (ii) to assess the predictive power of our in silico populations during the administration of three specific drugs (Diltiazem, Cisapride and Astemizole) plus a fourth drug (Dofetilide) as positive control.
Methods

Experimental dataset
The experimental dataset consists in APs and CaTrs optically recorded from hiPSC-CMs syncytia (CDI iCell 2 cardiomyocytes) at room temperature under non-paced conditions. Recordings were performed in control conditions and after administration of one of the following drugs: Diltiazem (mainly an ICaL blocker), Cisapride and Astemizole (both mainly IKr blockers). In detail, recordings were performed on three plates (384-well format), where APs and CaTrs were recorded in negative control (administration of 0.1% DMSO, C-) and then administered with four increasing doses (D1, D2, D3 and D4) of Diltiazem (Plate 1), Cisapride (Plate 2) and Astemizole (Plate 3). Furthermore, 0.5 nM Dofetilide was tested on all the plates as positive control (C+). APs and CaTrs were recorded from five C-samples and from six samples each of C+, D1, D2, D3 and D4. Experimental biomarkers for the three plates are reported in Table 1 . For each biomarker, we had five measurements in C-and six measurements in the other conditions. Biomarkers are: AP and CaTr cycle length (Vm CL and Ca CL), duration at 30%, 50% and 90% of AP (APD30, APD50 and APD90) and of CaTr (CTD30, CTD50, CTD90), AP and CaTr triangulation (Vm Tri90-30=APD90-APD30 and Ca Tri90-30=CTD90-CTD30) and CaTr time to rise from 10% to 90% (Ca tRise). For each plate and biomarker, we considered as lower bounds (LBi, LB3SD,i) the smallest of mean-2SD and mean-3SD, while as upper bounds (UBi, UB3SD,i) the maximum of mean+2SDand mean+3SD of the five control measurements for the biomarker i (see Table 1 , values in bold for ±2SD and in italic for ±3SD).
2.2.
In silico modeling
Adapting the hiPSC-CM model to room temperature
Simulations were performed with the recently published Paci2018 hiPSC-CM model [3] , which was tuned and validated to simulate APs and CaTrs at 37°C. To simulate the aforementioned experiments, we adapted the model to room temperature (21°C) by rescaling the model time constants for the main ionic currents according to the Q10 factors reported in Table 2 . 
Multi-objective genetic algorithms
Instead of a canonical approach to develop a population of in silico models, as in [8, 9] , here we opted for multiobjective genetic algorithms (MoGAs) [10] : they allow the concurrent optimization of many fitness functions, to find an optimal population. We chose to sample the following , where bi,sim is the i-th simulated biomarker, LBi the i-th experimental lower bound for bi,sim, UBi the i-th experimental upper bound for bi,sim and Nbiomarkers the number of biomarkers computed on the experimental APs (5 biomarkers) and CaTrs (6 biomarkers). Shortly, if the simulated i-th biomarker is smaller than LBi or greater than UBi, the error is computed as the squared distance between the simulated biomarker and the bound, normalized by the center of mass of [LBi, UBi]. The biomarkers used to constrain the fitness functions are listed in Section 2.1 and 
Drug tests
To assess the predictive power of our three populations of hiPSC-CM models, we then simulated Diltiazem, Cisapride, Astemizole and Dofetile (C+) at the four doses tested experimentally. Of note, the biomarkers computed on APs and CaTrs after drug administration were not used for the parameter set identification with MoGAs. Drug administration was simulated with the single pore block model on the three control populations, as in [8] . In Table  3 we reported the IC50 and the Hill's coefficients for the four drugs, together with the experimentally administered doses and the blocking effects on the ionic currents. Figure 1 compares the Paci2018 APs at 37°C and 21°C: as expected, the rate of spontaneous APs is slower and APD is longer at 21°C. This step helped also shifting AP and CaTr biomarkers closer to the experimental values recorded in C-conditions. MoGAs optimization produced three in silico control hiPSC-CMs populations, each representing the variability of a specific experimental plate. We then tested on each of these populations the corresponding drug which was tested experimentally. Specifically, Plate 1 (Diltiazem) contains 130 models, while Plate 2 (Cisapride) and Plate 3 (Astemizole) 200 models. D1, D2, D3 and D4 of the plate-specific drugs (Diltiazem was not simulated at D4). The population biomarkers are perfectly included within the experimental variability ranges for C-, thanks to the calibration process. However, drug simulations (D1, D2, D3 and D4) are also in agreement with the drug-induced changes observed in the experiment, although these experiments were not used for the optimization process. For example, Diltiazem shortens APD90 and reduces Vm Tri90-30. Conversely, Cisapride and Astemizole prolong APD90 and CTD90, increase Ca tRise and the triangulation of both AP and CaTr.
Results
Conclusions
In this work we proposed a proof-of-concept optimization of in silico populations by means of MoGAs. We observed in particular that by optimizing an in silico population on the control experiments of different plates, we then obtain qualitative agreement between simulated and experimental drug effects, without using for a following optimization the experimentally recorded data on the same plate after drug administration. However, for some of the biomarkers, e.g. APD50 and APD30, for all the three drugs, especially at the highest drug doses, the simulated drug effects look amplified compared to experiments, possibly due to nonspecific and/or multi-channel drug effects experimentally that are not reflected in the model. This work therefore shows that optically-obtained data are suitable for tuning populations of in silico models of hiPSC-CMs and that MoGAs represent an alternative, or can be combined, to canonical approaches for generating populations of in silico models.
